FP 02.2

Drug Profile

FP 02.2

Alternative Names: FP 02; FP-02-2; FP02.2; Hepsyn-B™; HepTcell

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Targeting Systems
  • Developer Altimmune
  • Class Hepatitis B vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 30 Sep 2017 Altimmune completes enrolment in a phase I trial for Hepatitis B in United Kingdom and South Korea before September 2017
  • 01 Sep 2015 Vaxin is now called Altimmune
  • 21 Jul 2015 Vaxin receives a Notice of Allowance from USPTO for Hepatitis B virus infection in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top